The Digital Mammography DREAM Challenge.
Spring 2016 (Pre-registration Opens October 7)
This Challenge, one of two large prize Coding4Cancer Challenges, seeks to improve the accuracy of breast cancer detection and reduce the current rate of patient callbacks.
ICGC-TCGA SMC-DNA Meta Challenge
August 2015- Fall 2015 (Now Open)
The ICGC-TCGA DREAM Somatic Mutation Calling Meta-pipeline Challenge (SMC-DNA Meta) (herein, The Challenge) is an international effort to improve standard methods for identifying cancer-associated mutations and rearrangements in whole-genome sequencing (WGS) data.
AstraZeneca-Sanger Drug Combination Prediction DREAM Challenge
Fall 2015 (Now Open!)
This Challenge is designed to explore fundamental traits that underlie effective combination treatments and synergistic drug behavior using baseline genomic data, i.e. data collected pretreatment.
DREAM 10 – ICGC-TCGA DREAM Somatic Mutation Calling Tumor Heterogeneity Challenge (SMC-Het)
Nov 2015- May 2016 (Now Open!)
This challenge’s focus is to identify the best subclonal reconstruction algorithms and to identify the conditions that affect their performance - binary options robots.
ICGC-TCGA DREAM Somatic Mutation Calling RNA Challenge (SMC-RNA)
Winter 2016 (Pre-Registration Open)
The goal of the somatic mutation calling (SMC) Challenge is to identify the most accurate mutation detection algorithms, and establish the state-of-the-art. The algorithms in this Challenge must use as input WGS data from tumor and normal samples and output mutation calls associated with cancer.
An international consortium of groups from Canada, the United States and the United Kingdom have come together to create an innovative, cloud-based, public challenge running on the Google Cloud Platform to optimize the discovery of genetically distinct groups of cells within cancers that could respond differently to treatment and have different risk of spreading. (Read more)
Each year, more than 5,600 Americans are diagnosed with Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s Disease. This diagnosis usually prompts more questions from patients and family members about longevity and quality of life than what physicians can immediately answer. (Read more)
Today, Prize4Life, Sage Bionetworks and the DREAM community announced the winners of the DREAM ALS Stratification Prize4Life Challenge, a global data analysis competition to computationally identify different subgroups of ALS patients. In ALS, there is currently no way to determine whether someone living with the disease will survive the average of 3-5 years after diagnosis or live with ALS for decades. The goal of the Challenge is to find answers that may inform clinical practice, mexedrone, and ultimately personalized approaches to the discovery and development of new ALS medicines. (Read more)